Phase II study of MLN518 in patients with metastatic clear cell renal cell carcinoma

Trial Profile

Phase II study of MLN518 in patients with metastatic clear cell renal cell carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2013

At a glance

  • Drugs Tandutinib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2010 Actual patient number (10) added as reported by ClinicalTrials.gov.
    • 28 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Oct 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top